Thursday, April 6, 2017
New York Times (Apr. 4, 2017): Does Birth Control Cause Depression? by Aaron E. Carroll:
A study published in the Journal of the American Medical Association Psychiatry suggests that hormonal contraceptive use may trigger depression. The study examined all women and adolescent females in Denmark from 2000 through 2014. It found that those who used hormonal contraceptives "had significantly higher risks of also taking an antidepressant." The risks were higher in adolescents than in women and decreased as the subjects aged.
Placed in the context of other studies that have examined hormonal contraceptive use, the study comes up short. It's not a controlled trial and does not even remotely establish causation. It is also easy to criticize it on the basis that "anti-depressant use isn't the best measure of new-onset depression."
Data from other studies appear to contradict the JAMA study: "the data that do exist show that most women don't show any effect from hormonal birth control, or actually had their mood improve. Moreover, "women who have underlying mood disorders were more predisposed to have mood-related side effects." The JAMA introduces intriguing and "newsy" findings into the mix, but is by no means the last word on the subject. The topic of hormonal birth control and mood is best explored in the context of the patient-physician relationship. When viewed up against the fact that birth control is "[o]ne of the biggest American victories of the last decade," the fact that it may contribute to depression may be a risk worth taking.
Friday, September 23, 2016
New York Times (Sept. 19, 2016): Want a Zika Test? It's Not Easy, by Roni Caryn Rabin:
Getting a Zika test is harder than you thought, even for people who have recently traveled to areas where Zika is a big problem and who are planning to have children. People are discovering that you cannot simply show up at a public health department and be tested on demand.
The difficulty stems from a Centers for Disease Control directive establishing strict guidelines for Zika testing. The guidelines give priority to pregnant women with possible exposure to Zika and to people with Zika-like symptoms. This leaves out people who have possibly been exposed to Zika and are trying to conceive. The guidance for this population is that they engage in protected sexual intercourse for at least eight weeks after their fear exposure. The World Health Organization recommends six months of protected sexual intercourse before trying to conceive. These recommendations are meant to prevent an onslaught of requests for Zika testing that would swamp local public health authorities. They also help define when insurers will cover Zika testing.
Testing for Zika is a complex process that may require three tests for a conclusive result. There is no test for detecting the infection in semen, however.
Monday, September 5, 2016
New York Magazine (August 22, 2016): How New York City Is Fighting the Growing Threat of Zika, by Charley Lanyon
With Zika on the rise in places further South like Florida, New York City is taking note of the failure of adequate preparation in other states to avoid the spread of the virus. While the common carrier of the virus, the Aedes aegypti mosquito, generally doesn't fly as far up as New York City, the related Asian Tiger mosquito does bite in New York, and some are worried that they too could become carriers of the virus. New York wants to target mosquitos in a different and more aggressive way, and intends to use a significant portion of its budget to do so:
Thus, the city is going after the Asian tiger mosquito hard, with large-scale predawn insecticide sprayings from the backs of pickup trucks and smaller more-targeted assaults from teams of exterminators with backpacks full of mosquito poison that focus on areas believed to be especially high-risk.
Even with all of the precautions, city officials are quick to reiterate that there has not been a single case of mosquito- transmitted Zika in New York City, and they are hopeful that there will never be one. The biggest danger for catching Zika in the city is through unsafe sexual contact with an individual who has been infected abroad. So at least for now, the ability to control the spread of Zika in New York lies as much with the individual as the city. Be safe.
Sunday, September 4, 2016
New York Magazine (August 12, 2016): New York City Buildings Are Now Required to Have Lactation Rooms, by Laura June
A bill requiring some New York City-run buildings to have rooms allocated specifically for lactation as of July 2017 was passed unanimously by the City Council and signed by Mayor de Blasio. There will be no restroom facilities in the rooms, but they will be equipped with electrical outlets for pumps. New York job center buildings, medical centers, and borough offices owned by the City are just some of the buildings protected by the new law.
Mayor de Blasio said in a statement, "This bill is about fairness, access, and health — no new mother should be unable to breast-feed because she can’t find a private space." He added that the "bill takes our city one step toward being a place where all women feel comfortable breast-feeding whenever they need to, wherever they need to.”
Wednesday, August 3, 2016
New York Times (July 19, 2016): I.V.F. Does Not Raise Breast Cancer Risk, Study Shows, by Catherine Saint Louis:
The use of estrogen and progesterone in in vitro fertilization has in the past stoked fears that the procedure could place patients at risk of developing breast cancer. A retrospective analysis published in 2008 found found "a potential increase in breast cancer among I.V.F. patients older than 40." But later studies, in Israel and Australia, suggested more of a danger for younger women. Some believed that infertility itself might be linked to breast cancer.
Several studies conducted in recent years, however, suggest that the fear is unfounded. The most comprehensive of these studies, published in July in the Journal of the American Medical Association, found "no increased risk among women who have undergone I.V.F." The study likewise found no increased risk among women who had less invasive treatments for infertility. Oddly, the study emphasized what appeared to be a reduced risk of breast cancer among women who have submitted to I.V.F. multiple times.
The JAMA study is not conclusive. More research needs to be conducted, including on the risk of breast cancer in postmenopausal women who have had I.V.F.
Thursday, July 21, 2016
The Guardian (July 18, 2016): Doctors urged to advise patients about risks of abstinence-centric sex education, by Molly Redden:
In a recently released report, The American Academy of Pediatrics denounced abstinence only education programs, stressing the importance of educating young people about comprehensive approaches to things like STIs and contraception. Some interviewed view this as a triumph for doctors in areas where parents may want to mitigate their children gaining access to this kind of information, viewing the report as a scientifically-sound back up against the arguments of abstinence-focused parents. The report stresses the inadequacy of abstinence-only education and highlights conversations about consent and gender identity as a few of the topics pediatricians should feel encouraged to speak with patients about.
Abstinence-only groups have already taken issue with the report, but many are heralding this as an important step in the right direction for doctors and patients alike:
“This is the mothership telling pediatricians that talking about sex is part of your charge to keep children and adolescents safe,” said Dr Cora Breuner, a professor and pediatrician at Seattle Children’s research hospital and the report’s lead author.
Monday, July 18, 2016
The Atlantic (July 13, 2016): Why the Male Pill Still Doesn't Exist, by Andy Extance
While America was introduced to the female birth control pill, and the first tests in hopes of creating a pill for men were conducted as early as 1957, many lament the fact that a male 'pill' equivalent to that of female hormonal contraception still does not exist. There are a variety of issues that have delayed the development of a male pill - there is a lack of commitment to contraception; pharmaceutical companies are less interested in making a product for men; and dangerous side effects documented from previous drug trials. But studies show that the interest, across gender identities, for a male pill is there. The article highlights the social acceptance of women bearing the responsibility of taking contraception, and researchers' worry that they may not be able to create a product that would be as easy as to administer as the female pill. Over the years, researchers have explored various hormonal and non-hormonal methods. One of the researches believes that the answer is probably out there and the work just needs to be completed:
[Elaine] Lissner is adamant that the ideas that seem to have faltered are not dead, they’re just resting. “We keep collecting new methods and never finish the ones we have,” she fumes. “Pick one and make something! Finish the job!”
Monday, June 6, 2016
New York Times (May 30, 2016): Triplet and Higher-Order Births in U.S. Down 41%, by Nicholas Bakalar:
Women 25 and older and in particular women 45 and older are giving birth to fewer higher-order births, 90 percent of which have been triplets in recent years. The sharpest drop occurred among non-Hispanic white women, though the rate in this group is still 57 percent higher than for non-Hispanic black women and twice as high as the rate for Hispanic women. The increase in higher-order births prior to 1998 was attributed to the rising average maternal age. This average has continued to rise; the decline in higher-order births, then, is thought to be the result of the practices of infertility centers, namely, not implanting multiple embryos in women seeking treatment.
Wednesday, June 1, 2016
Human Reproduction (May 21, 2016): Santa Claus in the Fertility Clinic, by Hans Evers:
The editor-in-chief of this premier medical journal criticizes infertility physicians for creating therapeutic illusions with misdiagnoses, useless medications, and unnecessary treatment. Evers is referring specifically to the unnecessary use of intra-cytoplasmic sperm injection (ICSI) in cases where in vitro fertilization (IVF) by itself would be sufficient to create a viable pregnancy. ICSI is indicated in cases of male-factor infertility, but such cases do not comprise the majority of infertility cases. Evers bases his evaluation on data covering 2008 through 2010 and gathered by the International Committee Monitoring Assisted Reproductive Technology (ICMART). The data show that the ICSI-to-IVF ratio varies from 1.4 in Asia to a staggering 60.3 in the Middle East. Studies show that the use of ICSI in non-male-factor infertility cases results in fewer lives births than the use of IVF alone. It does not improve the chances of a successful fertilization in such cases. Evers calls for the end of this costly and ineffective therapeutic illusion.
Wednesday, May 11, 2016
New York Times (May 3, 2016): Silence Order on Abortions Violates Law, Doctor Says, by Erik Eckholm:
Diane J. Horvath-Cosper, an obstetrician and gynecologist at Med-Star Washington Hospital Center has filed a federal civil rights complaint against Med-Star in the wake of the hospital's order that she cease speaking out in favor of abortion liberty. The hospital has required Dr. Horvath-Cosper to turn down "several requests for interviews or articles or risk losing her job." The hospital says that the order is a "sensible precaution" because it fears violence in the current fraught climate. Dr. Horvath-Cosper and some of her colleagues believe that staying silent about abortion "feeds the drive to stigmatize and restrict abortion." "'I don't think the way to deal with bullies is to cower and pull back," she said.'" The chair of Physicians for Reproductive Health, a national advocacy group, commented that physicians who speak out about abortion are making a personal decision based on privacy and risk. If the complaint moves forward, the hospital risks losing its federal funding.
Friday, May 8, 2015
TIME: How a New Study on Premature Babies Could Influence the Abortion Debate, by Eliza Gray:
A new study showing that a tiny percentage of extremely premature babies born at 22 weeks can survive with extensive medical intervention could change the national conversation about abortion, though the research is unlikely to have a major effect on women’s access to abortions in the short term.
Pro-life advocates said the study—which was published by theNew England Journal of Medicine on Wednesday and found that 3.5% percent of 357 infants born at 22 weeks could survive without severe health problems if hospitals treated them—could benefit the pro-life movement by sparking discussion about the viability of premature babies. . . .
This article correctly points out that the study in no way contradicts or forces reconsideration of Supreme Court precedent governing pre- and post-viability abortions. Unlike what some articles suggest, the Supreme Court has never set viability at a specific point in pregnancy (even in Roe), but rather has left the determination of viability to the provider to determine based on the individual facts surrounding each pregnancy. Viability depends on many factors, including the type of medical facilities available.
Monday, December 8, 2014
Bustle: An Anti-Choice Group Is Pushing "Abortion Reversal" Treatment, And It's Alarming To Say The Least, by Jessica Blankenship:
In Bettendorf, Iowa, an anti-choice advocacy group is offering women an “abortion reversal” using an experimental treatment about which little is known, and it’s all decidedly suspect and troubling. The Women’s Choice Center (which is, to reiterate, is run by a pro-life/anti-choice group) is now promoting what they’re touting as a chance for women who are in the middle of a medical abortion the chance to “unabort” their pregnancies. The major problem with this is that the therapy hasn’t really been tested, and the entire procedure just generally feels problematic all around: imploring women to undergo experimental-at-best, hormone-altering treatments, underscored, obviously, by an anti-choice agenda.
Here’s how this whole thing, more or less, supposedly works . . . .
Saturday, March 1, 2014
Study Finds that Men's "Biological Clock" Means Higher Risk of Mental Illness in Children Born to Older Fathers
The New York Times: Mental Illness Risk Higher for Children of Older Fathers, Study Finds, by Benedict Carey:
Children born to middle-aged men are more likely than those born to younger fathers to develop any of a range of mental difficulties, including attention deficits, bipolar disorder, autism and schizophrenia, according to the most comprehensive study to date of paternal age and offspring mental health. . . .
. . . Men have a biological clock of sorts because of random mutations in sperm over time, the report suggests, and the risks associated with later fatherhood may be higher than previously thought. The findings were published on Wednesday in the journal JAMA Psychiatry. . . .
The Los Angeles Times: Study calls DNA test reliable in discovering fetal disorders, by Monte Morin:
The screening more accurately identifies likely cases of genetic disorders caused by extra chromosomes, like Down syndrome, in a study of low-risk pregnant women.
It's billed as a faster, safer and more accurate way of screening expectant mothers for fetal abnormalities like Down syndrome, and proponents say it has already become the standard for prenatal care.
But as a handful of California companies market their DNA-testing services to a growing number of pregnant women, some experts complain that the tests have not been proven effective in the kind of rigorous clinical trials that are required of new drugs.
Now, a study published Wednesday by the prestigious New England Journal of Medicine has verified that one of the tests can identify likely cases of Down syndrome and other genetic disorders caused by extra chromosomes in low-risk women with greater reliability than traditional noninvasive screening methods. . . .
Saturday, February 1, 2014
The New York Times: Responding to Critics, Gynecology Board Reverses Ban on Treating Male Patients, by Denise Grady:
After months of protest from doctors and patients, a professional group that certifies obstetrician-gynecologists has lifted a ban it imposed in September and now says its members are free to treat men.
The decision, announced Thursday by theAmerican Board of Obstetrics and Gynecology, was a reversal of its September directive, and followed partial concessions the group had made in November and December in an effort to mollify critics. . . .
Saturday, January 25, 2014
TIME: Effectiveness of Emergency Contraception for Overweight Women Reviewed in Europe, by Alexandra Sifferlin:
The European Medicines Agency (EMA) — the European version of the U.S. Food and Drug Administration (FDA) — launched a broad review of whether body weight influences the ability of emergency contraceptives to prevent unintended pregnancies.
The agency recently required makers of the European version of Plan B, called Norlevo, to add an alert that the product may be less effective for overweight women. . . .
Tuesday, November 19, 2013
NPR: Using Birth Control Pills May Increase Women's Glaucoma Risk, by Nancy Chute:
Taking birth control pills may increase a woman's risk of eye disease later in life, a study finds, because they may reduce protective levels of estrogen. . . .
In this study, researchers looked at data on 3,406 women over 40 who participated in a bignational health survey administered by the Centers for Disease Control and Prevention. The women who had taken oral contraceptives for more than three years were more than twice as likely to be diagnosed with glaucoma.
But the absolute risk of getting glaucoma after age 40 is small, about 1.86 percent, according to the CDC. So doubling that risk would bring it up to a bit under 4 percent.
And there's no proof that taking birth control pills, which contain hormones that keep estrogen levels from peaking midway through a woman's monthly cycle, cause the apparent increased risk. . . .
Wednesday, July 31, 2013
The New York Times: HPV Vaccine Not Reaching Enough Girls, C.D.C. Says, by Sabrina Tavernise:
The very low vaccination rate for teenage girls against the human papillomavirus — the most common sexually transmitted infection and a principal cause of cervical cancer — did not improve at all from 2011 to 2012, and health officials on Thursday said a survey found that doctors were often failing to bring it up or recommend it when girls came in for other reasons. . . .
Tuesday, July 23, 2013
The Boston Globe: Plan B One-Step gets exclusive rights, by Deborah Kotz:
The US Food and Drug Administration decided late Monday night to grant exclusive rights to Teva Pharmaceuticals to put its brand name form of emergency contraception on drugstore shelves without any age restrictions for the next three years. Plan B One-Step, Teva’s product, has started to appear in some drugstores this week on shelves next to spermicides and pregnancy tests. . . .
Wednesday, May 1, 2013
The Hill - Healthwatch Blog: FDA approves 'morning-after pill' for women 15 and up, by Sam Baker:
The Food and Drug Administration said Tuesday that the contraceptive known as Plan B should be available without a prescription for all women 15 and older.
The move is sure to stir controversy among social conservatives, some of whom view Plan B as a form of abortion. Unlike other forms of birth control, Plan B is intended for use after sex, rather than before. . . .
The Hill - Healthwatch Blog: FDA pressed to go further on Plan B, by Sam Baker:
The Food and Drug Administration (FDA) is under pressure from political activists — and some doctors — to remove all age restrictions on the over-the-counter sale of Plan B.
The FDA made waves Tuesday by allowing the sale of Plan B without a prescription to women 15 and older. Its previous policy had restricted the drug to patients 17 and older.
Women's-health advocates said the move from 17 to 15 was a good first step, but doesn't go far enough. . . .
RH Reality Check: Administration Again Fails on Over-the-Counter Emergency Contraception, by Jodi Jacobson:
Today, in a proposal that can best be described as adding insult to injury, the Food and Drug Administration (FDA) approved making emergency contraception (EC) available over-the-counter for teens and women ages 15 and up. This convoluted proposal from the Obama administration comes despite a court order in early April by U.S. District Court Judge Edward R. Korman to make EC available over-the-counter to all ages within 30 days of his decision. It comes from an administration which pledged to make science the cornerstone of public policy and instead has consistently flouted a wealth of accumulated evidence on emergency contraception. It also comes after several studies showing that current policy requiring prescriptions for some groups and not others has confused so many pharmacists that access to EC has been denied to many who were in fact legally eligible to obtain it quickly. In practice, the new policy will almost certainly perpetuate, not resolve, that confusion. . . .
The Nation: Hey, FDA: Drop the Plan B Restriction, by Jessica Valenti:
Yesterday, the FDA announced that it will make Plan B—also known as emergency contraception (EC) or the morning after pill—available over the counter to women older than 15 years old who can prove their age. This decision comes less than a week before the end of a thirty-day deadline imposed by a federal judge mandating EC be available without a prescription to women of all ages. So despite the FDA’s announcement, the Obama administration still needs to appeal the judge’s decision or request a stay by Monday. . . .